Companies + Stocks
Public companies and startups, pipelines, partnerships, funding and milestones — scientific progress kept separate from market performance.
The Biotech Startup Map: How Young Companies Move From Discovery to Patients
From a university patent to a pharmacy shelf, young biotech companies follow a route with predictable stations, forks and dead ends.
Latest in Companies + Stocks
Companies + StocksHow to Research a Biotech Stock Without Confusing a Great Story With Great Evidence
Biotech companies tell two stories at once: one scientific, one financial. This educational guide, which is not investment advice, shows how to check primary sources like SEC EDGAR, ClinicalTrials.gov and FDA databases.
Companies + StocksFrom University Lab to Startup: How Medical Discoveries Become Products
Most medical products begin as university research, then pass through tech transfer offices, licences or spinouts, and the regulatory system. This guide maps each step and the reasons discoveries stall.
Companies to know
A mix of listed companies and private startups. Profiles describe science and pipeline stage — they are informational, not investment advice.
Vertex Pharmaceuticals
Nasdaq: VRTXVertex develops small-molecule and genetic medicines for serious diseases and is best known for its cystic fibrosis drugs. It co-developed Casgevy, the…
CRISPR Therapeutics
Nasdaq: CRSPCRISPR Therapeutics is a gene-editing company that co-developed Casgevy with Vertex. Its clinical pipeline includes in vivo editing programs for cardiovascular targets…
insitro
Not publicly tradedinsitro, founded by Daphne Koller, combines machine learning with human cellular data to identify disease drivers and design drug candidates. It has…
Moderna
Nasdaq: MRNAModerna develops mRNA medicines and markets vaccines against COVID-19 and RSV. With Merck, it is developing intismeran autogene, an individualized neoantigen mRNA…
Intuitive Surgical
Nasdaq: ISRGIntuitive makes the da Vinci robotic-assisted surgical systems used in minimally invasive procedures. Its fifth-generation platform, da Vinci 5, adds force-sensing instruments…
Altos Labs
Not publicly tradedAltos Labs studies cellular rejuvenation — resetting aspects of cell state to restore health and resilience. It has research sites in the…
Illumina
Nasdaq: ILMNIllumina makes DNA sequencing instruments, reagents and software used widely in research and clinical genomics. It acquired GRAIL in 2021 and separated…
Recursion Pharmaceuticals
Nasdaq: RXRXRecursion describes itself as a clinical-stage 'TechBio' company that combines automated biology and machine learning to find drug candidates. Its most advanced…
Retro Biosciences
Not publicly tradedRetro Biosciences aims to extend healthy human lifespan through programs in autophagy, cell replacement and tissue reprogramming. Its lead oral drug, RTR242,…
GRAIL
Nasdaq: GRALGRAIL develops blood tests for early cancer detection; its Galleri multi-cancer early detection test is sold in the U.S. as a laboratory-developed…
Hyperfine
Nasdaq: HYPRHyperfine makes the Swoop system, a portable, ultra-low-field MRI scanner for brain imaging at the point of care. The company was founded…
NewLimit
Not publicly tradedNewLimit develops epigenetic reprogramming medicines intended to restore youthful function to aged cells, starting with liver cells. It was co-founded by Brian…
Company profiles and watchlists are informational. Scientific progress is not the same thing as investment performance, and a compelling technology never guarantees a rising stock.
The Spin Watchlist
Companies we follow closely, with the scientific milestones that matter. Science first; share prices are a separate question.
| Company | Status | Ticker | Most advanced stage | What to watch | Market data | Profile verified |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics | Public | CRSP | Approved/marketed products | — | Not connected | 2026-09-25 |
| GRAIL | Public | GRAL | Approved/marketed products | — | Not connected | 2026-09-25 |
| Hyperfine | Public | HYPR | Approved/marketed products | — | Not connected | 2026-09-25 |
| Illumina | Public | ILMN | Approved/marketed products | — | Not connected | 2026-09-25 |
| Intuitive Surgical | Public | ISRG | Approved/marketed products | — | Not connected | 2026-09-25 |
| Moderna | Public | MRNA | Approved/marketed products | — | Not connected | 2026-09-25 |
| Recursion Pharmaceuticals | Public | RXRX | Phase 2 | — | Not connected | 2026-09-25 |
| Vertex Pharmaceuticals | Public | VRTX | Approved/marketed products | — | Not connected | 2026-09-25 |
Static example Live market data is not connected yet, so no prices are shown. When a reliable data source is connected, each price will display its source and timestamp. This watchlist is informational and is not a recommendation to buy or sell any security.
From The Lab
What if we could print living tissue that functions inside the body?
Printing shapes is easy. Printing tissue that lives, breathes and connects is not.
Watch and learn
Explaining Clinical Trials
The European regulator explains what clinical trials are, why they are run in phases, and how participants are protected. A good baseline for reading…
5 Things You Need to Know About the Drug Approval Process
The FDA outlines key facts about how a new medicine moves from development to approval. It clarifies what regulators review and what an approval…
Explore other frontiers
The Spin Brief
One concise weekly roundup of what moved in medicine — what happened, what the evidence shows, and what to watch next. No hype, no stock tips.
- Five stories that mattered, each with its own Spin
- One stage change in the pipeline tracker, sourced
- One Lab question to think about
We use double opt-in: check your inbox to confirm. We never sell your address, and we never ask for health or genetic information.